Health Care·Health Care Equipment·$92.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.18 | N/A | +65.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.18 | N/A | +65.14% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook on the company's performance. They emphasized their commitment to innovation and market expansion.
Management highlighted strong performance in key product areas.
They expressed confidence in future growth despite not providing specific guidance.
Boston Scientific's strong EPS performance, exceeding expectations significantly, led to a 3.5% increase in stock price. Investors reacted positively to the company's ability to outperform on earnings, even without revenue figures or specific guidance. The management's optimistic tone suggests confidence in future growth, which may further bolster investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BIOGEN INC
Jan 28, 2013